Svar Life Science And Lablytica Life Science Announce Strategic Partnership To Expand Bioanalytical Services With Advanced LCMS/MS Capabilities

Svar Life Science, a leading provider of bioanalytical and diagnostic solutions, is proud to announce a strategic partnership with Lablytica Life Science, a Swedish contract research organization (CRO) specializing in advanced bioanalytical services. This collaboration significantly enhances Svar's CRO portfolio by integrating Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) capabilities, enabling comprehensive support for both small and large molecule drug development programs.

Through this partnership, Svar Life Science will help clients access Lablytica's GLPcertified LC-MS/MS services, which are essential for pharmacokinetics (PK), pharmacodynamics (PD), biomarker quantification, and therapeutic drug monitoring across all phases of drug development, from discovery to clinical trials.

"This partnership marks a major milestone in our mission to provide end-to-end, sciencedriven bioanalytical solutions," saidAnna Karaszewska, Product Manager, CRO Services at Svar Life Science. "By joining forces with Lablytica, we are expanding our capabilities to meet the growing demand for high-sensitivity, high-specificity analysis of complex biologics and small molecules. It's a strategic move that strengthens our position in the European CRO landscape and reinforces our commitment to scientific excellence."

Lablytica, based in Uppsala, Sweden, operates as a stand-alone CRO and brings over a decade of expertise in regulated bioanalysis. Their services include method development, validation, and sample analysis using state-of-the-art LC-MS/MS platforms, fully compliant with FDA, EMA, and ICH M10 guidelines.

"We are excited to partner with Svar Life Science to broaden the reach of our services," said David Pekar, CEO of Lablytica. "Together, we can offer clients a seamless and integrated bioanalytical experience, tailored to the evolving needs of modern drug development."

Key Benefits of the Partnership:

• Expanded Service Offering: Integration of LC-MS/MS with Svar's existing ligandbinding and cell-based assay platforms. • Regulatory Strength: Full GLP and GCP compliance across all analytical services.
• Therapeutic Versatility: Support for small molecules, biologics, antibody-drug conjugates (ADCs), peptides, oligonucleotides, and more.
• Client-Centric Collaboration: A shared commitment to scientific partnership, transparency, and tailored project support.
• Market Reach: Enhanced access to biotech, pharma, and CRO clients across Europe.

This collaboration positions Svar Life Science as a bioanalytical integration partner, delivering flexible, high-quality solutions for complex therapeutic programs. The partnership is part of Svar's broader strategy to drive innovation, expand market presence, and support the development of next-generation therapies.

About Lablytica Life Science
Lablytica specializes in bioanalytical services, including sample analysis in plasma, tissue samples, and urine. Research and development activities carried out at our facility in Uppsala, Sweden, are fully compliant with Good Laboratory Practice (GLP) and conform to regulatory guidelines from ICH M10. The laboratory is part of the Swedish OECD GLP regulatory inspection program from SWEDAC.

Lablytica is a spin-off company from Recipharm OT Chemistry in Uppsala, Sweden.

Since 2016, Lablytica has been part of the SWEDAC GLP inspection program for the performance of GLP analytical study phases. In November 2019, we became an independent company owned by the holding company Center for Translational Research.

About Svar Life Science
Svar Life Science AB is a Swedish company that works to enable personalized medicine by serving the global life science market with tools for drug development and companion diagnostic solutions.

We deliver answers you can trust from discovery to diagnosis - our combination of high-quality products, innovative technologies and comprehensive laboratory services are used by our customers to discover new therapeutics, diagnose patients and treat diseases.

You can be sure of our answers: we’ve been working right across the clinical diagnostic value chain for more than 30 years. 

Explore our competitive solutions for drug development and clinical diagnostics on www.svarlifescience.com